potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)

There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).

FDA is adding a black box warning to these topical immunosuppressants used for eczema. Patients will soon get a Medication Guide when their prescriptions are filled.

It's NOT known for sure if these drugs increase cancer risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote